As of May 25, 2025, Delta 9 Cannabis Inc (DN.TO) reports a EV/EBITDA of -8.56.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Delta 9 Cannabis Inc's EV/EBITDA to Peers
To better understand Delta 9 Cannabis Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Delta 9 Cannabis Inc (DN.TO) | -8.56 |
| Cipher Pharmaceuticals Inc (CPH.TO) | 27.87 |
| Emmaus Life Sciences Inc (EMMA) | 19.59 |
| Biosyent Inc (RX.V) | 13.24 |
| Aoxing Pharmaceutical Company Inc (AOXG) | 10.91 |
| Medicine Man Technologies Inc (SHWZ) | 6.23 |
Compared to its competitors, Delta 9 Cannabis Inc's EV/EBITDA is among the lowest compared to peers, which may indicate undervaluation or market concerns about future performance.